Cancer Family
Stromal Neoplasm
CI-CAN-00000360Explore in graph →
Non-malignant52 active trials2 approved drugs89 evidence items
- NCIt
- C6781
Loading cancer entity…
Cancer Family
CI-CAN-00000360Explore in graph →
Clinical trials
355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04924075 | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) | recruiting | Phase 2 | 355 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Sep 25, 2026 | clinicaltrials |
| NCT06441331 | Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors(KinLET) | recruiting | Phase 1 | 20 | ITM Solucin GmbH |
| 3 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT07124000 | DESTINY-PANTUMOUR04(DP-04) | recruiting | — | 100 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07585266 | A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) | recruiting | Phase 3 | 800 | GlaxoSmithKlineINDUSTRY | 15 | Sep 24, 2026 | clinicaltrials |
| NCT07837271 | Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST | active not recruiting | — | 288 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00265798 | Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05493215 | Imatinib TDM in GIST | recruiting | Phase 2 | 28 | Reema A. PatelOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT04557969 | Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis | recruiting | — | 400 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07406633 | KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) | recruiting | Phase 2 | 46 | Kumquat Biosciences Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05443087 | TARGETed Therapy Drug MONITOring in DIGestive Oncology(TARGETMONITO) | recruiting | N/A | 330 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04595747 | Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) | active not recruiting | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07724626 | Hyperpolarized MRI for GIST on Imatinib(DNP_GIST) | not yet recruiting | — | 30 | Chang Gung Memorial HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05957367 | A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 94 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT06640361 | A Study of Olverembatinib in SDH-deficient GIST. | recruiting | Phase 3 | 40 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07618377 | Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments | recruiting | Phase 1 | 10 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06087263 | Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. | active not recruiting | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07697248 | LRG GIST Patient Registry | recruiting | — | 5,000 | The Life Raft GroupOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04821895 | Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients(GIST) | active not recruiting | — | 50 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05489237 | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | active not recruiting | Phase 1 | 276 | IDRX, Inc., a wholly owned subsidiary of GSK, LLCINDUSTRY | 11 | Jul 2, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673861 | Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients(CURTAIN) | recruiting | N/A | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03050268 | Familial Investigations of Childhood Cancer Predisposition(SJFAMILY) | recruiting | — | 1,500 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT07647068 | Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors | not yet recruiting | Phase 2 | 59 | Joal BeaneOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07379047 | Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)(GISTAR-1) | recruiting | Phase 2 / Phase 3 | 255 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 2 | Jun 10, 2026 | clinicaltrials |
| NCT07171203 | Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor | recruiting | Phase 1 | 18 | University of California, San DiegoOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07434843 | PH 2 Pemigatinib in SDH-deficient GIST(PEMIGIST) | recruiting | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07581977 | A Novel Two-Tooth Clip for ESD and EFTR of GIST | recruiting | N/A | 60 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07550582 | Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction(SAVE-GEJ) | enrolling by invitation | Phase 2 | 40 | Peking University People's HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06748690 | MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT | recruiting | N/A | 96 | Peking University People's HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07522762 | Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study | recruiting | — | 330 | The Netherlands Cancer InstituteOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03594422 | A Study of HQP1351 in Patients With GIST or Other Solid Tumors | recruiting | Phase 1 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05661643 | The Efficacy and Safety of Temozolomide in SDH-deficient GIST(GIST) | recruiting | Phase 2 | 29 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05905887 | Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor | recruiting | Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06326346 | GIST Oral Paclitaxel(Liporaxel) | recruiting | Phase 2 | 28 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07096609 | Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients(LONGIST) | recruiting | Phase 1 / Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03624244 | Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)(BFR-ESS) | recruiting | Phase 2 | 40 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07411118 | RCT of EFTR Versus STER for GIST Treatment | recruiting | N/A | 136 | Chinese University of Hong KongOTHER | 4 | Feb 13, 2026 | clinicaltrials |
| NCT07405125 | Safety of Robotic Surgery for GISTs at Special Anatomic Sites | recruiting | N/A | 182 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07394413 | Surgical Handling of Fertility-preserving Treatments for Cervical Adenocarcinomas(SHAFT) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03673501 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib(INTRIGUE) | active not recruiting | Phase 3 | 453 | Deciphera Pharmaceuticals, LLCINDUSTRY | 22 | Feb 5, 2026 | clinicaltrials |
| NCT06630234 | A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) | recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06655246 | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | recruiting | Phase 1 | 157 | Kura Oncology, Inc.INDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05245968 | A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | active not recruiting | Phase 1 | 78 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 5 | Jan 20, 2026 | clinicaltrials |
| NCT01048281 | Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma | recruiting | — | 100 | Stanford UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials